In short
UCART20X22 is an innovative cell therapy being studied in clinical trials for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL). This article explores the ongoing research, potential benefits, and important information about this new treatment approach for patients who have not responded to previous therapies.
At a glance
- Treatment Name
- UCART20X22
- Type of Therapy
- Universal Engineered Chimeric Antigen Receptor T-cells
- Target Condition
- Relapsed or refractory B-cell Non-Hodgkin Lymphoma
- Administration Method
- Intravenous injection
- Age Range for Trial
- 18 to 80 years
- Prior Treatments Required
- At least 2 lines of prior treatment
- Main Trial Objectives
- Assess safety, determine appropriate dose, evaluate effectiveness
- Key Eligibility Criteria
- R/R mature B-NHL, adequate organ function, ECOG status 0 or 1
- Key Exclusion Criteria
- Active infections, recent allogeneic stem cell transplant, active CNS lymphoma
What is UCART20x22?
UCART20x22 is an innovative medical treatment currently being studied for patients with certain types of blood cancers. It is classified as a cell therapy, which means it uses specially modified cells to fight disease. More specifically, UCART20x22 is a type of CAR T-cell therapy, where T-cells (a type of immune cell) are engineered to target and attack cancer cells.
What condition does UCART20x22 treat?
UCART20x22 is being developed to treat relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL). This is a type of blood cancer that affects B-cells, which are part of the immune system. "Relapsed" means the cancer has returned after treatment, while "refractory" means the cancer has not responded to treatment.
How does UCART20x22 work?
UCART20x22 works by targeting two specific proteins found on the surface of B-cells: CD20 and CD22. The therapy uses T-cells that have been genetically modified to recognize and attack cells displaying these proteins. This dual-targeting approach may make the treatment more effective against cancer cells.
Current Clinical Trial
UCART20x22 is currently being studied in a clinical trial called NatHaLi-01. This is a Phase 1/2a study, which means it's an early-stage trial designed to test the safety and initial effectiveness of the treatment. The trial has two main parts:
- Dose-Finding Part: This part aims to determine the safest and most effective dose of UCART20x22.
- Dose-Expansion Part: This part will further test the chosen dose in more patients to confirm its safety and effectiveness.
Who is eligible for the UCART20x22 trial?
The trial is open to patients who meet certain criteria, including:
- Adults aged 18 to 80 years
- Diagnosed with relapsed or refractory B-cell Non-Hodgkin Lymphoma
- Cancer that is positive for CD20 and/or CD22 proteins
- Have received at least two prior lines of treatment
- Have adequate organ function
- Have at least one measurable tumor
Who is not eligible for the UCART20x22 trial?
Some factors that may exclude a patient from participating include:
- Recent stem cell transplant or certain other therapies
- Active infections, including COVID-19
- Certain heart conditions
- Active central nervous system lymphoma
- Pregnancy or breastfeeding
What are the objectives of the UCART20x22 trial?
The main goals of the trial are:
- To assess the safety and tolerability of UCART20x22
- To determine the most appropriate dose for future studies
- To evaluate how well the treatment works against the cancer (its "antitumor activity")
- To study how long the treatment remains effective
How is safety monitored in the trial?
The trial closely monitors patients for any side effects or adverse events. This includes:
- Tracking the nature and severity of any side effects
- Monitoring for serious adverse events
- Assessing the effects of the lymphodepletion regimen (a preparatory treatment given before UCART20x22)
- Evaluating how patients' immune systems recover after treatment